ET receptor antagonist 3

Cat. No.:	HY-155739
Molecular Formula:	$C_{27}H_{28}N_6O_5S$
Molecular Weight:	548.61
Target:	Estrogen Receptor/ERR
Pathway:	Vitamin D Related/Nuclear Receptor
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	ET receptor antagonist 3 (compound 17d) is an orally active ET receptor antagonist (IC_{50}=0.26 nM), which can be used for research in pulmonary arterial hypertension (PAH). ET receptor antagonist 3 attenuates monocrotaline (HY-N0750) induced PAH in rat model[1].
IC_{50} & Target	IC50: 0.26 nM (ET receptor)[1]
In Vivo	ET receptor antagonist 3 (compound 17d) (150 mg/kg/d, 300 mg/kg/d; po; 48 h following MCT administration, for 21-26 d) results significant reduction in mPAP, and decreases the levels of HIF1α, ANP, and TNNI3 in MCT-exposed rats. And shows antioxidant profile and inhibits lipid peroxidation[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Panchal J, et al. Development of novel bosentan analogues as endothelin receptor antagonists for pulmonary arterial hypertension. Eur J Med Chem. 2023 Nov 5;259:115681.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA